Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of U3-1287 in Advanced Solid Tumors
jRCT2080221225Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of patritumab in bronchial carcinoma, breast cancer, colorectal cancer (CRC) and 12 more, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety and tolerability of U3-1287 and Pharmacokinetics of U3-1287.
02
Drugs
patritumab
03
Conditions
bronchial carcinomabreast cancercolorectal cancer (CRC)prostate cancer (PCa)ovarian cancer
Beyond the preview
Go deeper on jRCT2080221225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221225.